Search

Your search keyword '"Amaria, Rodabe N."' showing total 349 results

Search Constraints

Start Over You searched for: Author "Amaria, Rodabe N." Remove constraint Author: "Amaria, Rodabe N."
349 results on '"Amaria, Rodabe N."'

Search Results

2. Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

3. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

4. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

5. Neoadjuvant relatlimab and nivolumab in resectable melanoma

6. Contributors

7. Melanoma

8. B cells and tertiary lymphoid structures promote immunotherapy response

11. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

13. Coenzyme A fuels T cell anti-tumor immunity

14. Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients

15. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

17. Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma

19. Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma

20. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity

21. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

22. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

23. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

25. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy

26. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

28. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

32. Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune‐related adverse event reveal upregulation of toll‐like receptor 4/complement‐induced innate immune response and increased density ofT H 1T‐cells

33. Abstract CT107: Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors

34. Supplementary Figure Legends from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

35. Supplementary Tables 1 - 11 from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

36. Supplementary Figures from A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling

37. Supplementary Figures 1 - 13 from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

38. Supplementary Tables from A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling

39. Data from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

40. Data from A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling

41. Supplementary Figure Legends from A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling

42. Supplementary Figure from Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma

43. Figures S1-S9 from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression

44. Supplementary Table from Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma

45. Supplementary information from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression

46. Supplementary Figure and Supplementary Tables from Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome

47. Supplementary Table S2 from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression

48. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy

49. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

50. Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma

Catalog

Books, media, physical & digital resources